Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q2 EPS of ($0.54), $0.04 worse than the analyst estimate of ($0.50). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $1.34 million.

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.